Jiangsu Hengrui Medicine Co., Ltd. (600276.SS)
- Previous Close
44.69 - Open
45.50 - Bid 44.74 x --
- Ask 44.76 x --
- Day's Range
44.07 - 46.23 - 52 Week Range
35.51 - 50.50 - Volume
37,685,549 - Avg. Volume
27,524,798 - Market Cap (intraday)
285.46B - Beta (5Y Monthly) 0.22
- PE Ratio (TTM)
63.93 - EPS (TTM)
0.70 - Earnings Date Aug 15, 2024 - Aug 19, 2024
- Forward Dividend & Yield 0.16 (0.36%)
- Ex-Dividend Date Jun 8, 2023
- 1y Target Est
56.91
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, develops, manufactures, and commercializes drugs worldwide. The company is developing Camrelizumab, Pyrotinib, Fuzuloparib, Adebrelimab, Rezvilutamide, Famitinib, Dalpiciclib, SHR-1701, SHR-1501, SHR-A1811, SHR1459, Mecapegfilgrastim, Apatinib, Linperlisib, and SHR2554 for oncology indications; SHR4640, Retagliptin, SHR20004, SHR-1209, SHR3824, INS068, SHR7280, and SHR2285 for cardiovascular and metabolism indications. It is also developing SHR0302, Hetrombopag, Vunakizumab, and SHR-1703 for autoimmune indications; SHR0410, Imrecoxib, Remimazolam, and SHR8554 for pain; Oteseconazole and HRS9950 for anti-infection; and SHR8028, SHR8058, SHR-1707, and SHR-1222 for other indications. The company was founded in 1970 and is based in Lianyungang, China.
www.hrs.com.cn19,611
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 600276.SS
Performance Overview: 600276.SS
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 600276.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 600276.SS
Valuation Measures
Market Cap
285.46B
Enterprise Value
263.77B
Trailing P/E
63.93
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.14
Price/Book (mrq)
6.82
Enterprise Value/Revenue
11.31
Enterprise Value/EBITDA
54.52
Financial Highlights
Profitability and Income Statement
Profit Margin
19.00%
Return on Assets (ttm)
6.22%
Return on Equity (ttm)
10.77%
Revenue (ttm)
23.32B
Net Income Avi to Common (ttm)
4.43B
Diluted EPS (ttm)
0.70
Balance Sheet and Cash Flow
Total Cash (mrq)
21.77B
Total Debt/Equity (mrq)
0.19%
Levered Free Cash Flow (ttm)
5.96B
Research Analysis: 600276.SS
Company Insights: 600276.SS
600276.SS does not have Company Insights